eligibility_summary
Adults ≥18, advanced/relapsed pancreatic, esophageal, liver or ovarian cancer after ≥1 line or no standard option, measurable disease, WHO PS 0–2, life expectancy ≥3 mo, adequate organ function, prior toxicities ≤G2, negative pregnancy test and contraception. Exclude investigational drugs <4 w or steroids <1 w before leukapheresis, active autoimmune/immune deficiency (except hypothyroid, T1DM, mild skin-only), untreated/progressing CNS mets, pregnancy/breastfeeding, other contraindications.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: IL15-transpresenting WT1-targeted autologous dendritic cell vaccine (biologic, personalized cell therapy). Patient-derived DCs are engineered to present Wilms’ Tumor 1 (WT1) antigens and surface-display the IL-15/IL-15Rα complex (“transpresentation”). Mechanism: DCs prime and expand WT1-specific CD8+ cytotoxic and CD4+ helper T cells via MHC I/II, IL-15 transpresentation strongly stimulates CD8+ T cells and activates NK cells, boosting proliferation, survival, cytotoxicity, and memory. Targets/pathways: WT1-expressing tumor cells, DC cross-priming, IL‑15/IL‑15Rα signaling (JAK/STAT, PI3K-AKT, MAPK), NK-cell activation. Phase 1/2, single-arm in advanced esophageal, pancreatic, ovarian, and liver cancers.